CL2012002125A1 - Metodo para la purificacion de anticuerpos de una mezcla de proteina en un biorreactor; unidad operacional que se utiliza en el metodo antes descrito. - Google Patents

Metodo para la purificacion de anticuerpos de una mezcla de proteina en un biorreactor; unidad operacional que se utiliza en el metodo antes descrito.

Info

Publication number
CL2012002125A1
CL2012002125A1 CL2012002125A CL2012002125A CL2012002125A1 CL 2012002125 A1 CL2012002125 A1 CL 2012002125A1 CL 2012002125 A CL2012002125 A CL 2012002125A CL 2012002125 A CL2012002125 A CL 2012002125A CL 2012002125 A1 CL2012002125 A1 CL 2012002125A1
Authority
CL
Chile
Prior art keywords
bioreactor
antibodies
purification
protein mixture
operational unit
Prior art date
Application number
CL2012002125A
Other languages
English (en)
Inventor
Diderick Reinder Kremer
Randal William Maarleleld
Original Assignee
Dsm Ip Assets Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dsm Ip Assets Bv filed Critical Dsm Ip Assets Bv
Publication of CL2012002125A1 publication Critical patent/CL2012002125A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B01D15/325—Reversed phase
    • B01D15/327—Reversed phase with hydrophobic interaction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Método para la purificación de anticuerpos de una mezcla de proteína en un biorreactor; unidad operacional que se utiliza en el método antes descrito.
CL2012002125A 2010-02-12 2012-07-31 Metodo para la purificacion de anticuerpos de una mezcla de proteina en un biorreactor; unidad operacional que se utiliza en el metodo antes descrito. CL2012002125A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10153529 2010-02-12

Publications (1)

Publication Number Publication Date
CL2012002125A1 true CL2012002125A1 (es) 2012-09-28

Family

ID=42133600

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012002125A CL2012002125A1 (es) 2010-02-12 2012-07-31 Metodo para la purificacion de anticuerpos de una mezcla de proteina en un biorreactor; unidad operacional que se utiliza en el metodo antes descrito.

Country Status (15)

Country Link
US (1) US20130131318A1 (es)
EP (1) EP2534169A1 (es)
JP (1) JP2013519652A (es)
KR (1) KR20120118065A (es)
CN (1) CN102762585B (es)
AR (1) AR080163A1 (es)
AU (1) AU2011214361C1 (es)
BR (1) BR112012020254A2 (es)
CA (1) CA2787897A1 (es)
CL (1) CL2012002125A1 (es)
EA (1) EA201201132A1 (es)
IL (1) IL221072A0 (es)
MX (1) MX2012009283A (es)
TW (1) TW201144327A (es)
WO (1) WO2011098526A1 (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012030512A1 (en) * 2010-09-03 2012-03-08 Percivia Llc. Flow-through protein purification process
WO2012149197A2 (en) 2011-04-27 2012-11-01 Abbott Laboratories Methods for controlling the galactosylation profile of recombinantly-expressed proteins
US20140288278A1 (en) * 2011-10-31 2014-09-25 Joseph Nti-Gyabaah Chromatography process for resolving heterogeneous antibody aggregates
EP2791176B1 (en) 2011-12-15 2018-07-11 Prestige Biopharma Pte. Ltd. A method of antibody purification
US9181572B2 (en) 2012-04-20 2015-11-10 Abbvie, Inc. Methods to modulate lysine variant distribution
US9067990B2 (en) 2013-03-14 2015-06-30 Abbvie, Inc. Protein purification using displacement chromatography
US9150645B2 (en) 2012-04-20 2015-10-06 Abbvie, Inc. Cell culture methods to reduce acidic species
US9249182B2 (en) 2012-05-24 2016-02-02 Abbvie, Inc. Purification of antibodies using hydrophobic interaction chromatography
EP2682168A1 (en) 2012-07-02 2014-01-08 Millipore Corporation Purification of biological molecules
HK1211981A1 (en) 2012-09-02 2016-06-03 Abbvie Inc. Methods to control protein heterogeneity
US9512214B2 (en) 2012-09-02 2016-12-06 Abbvie, Inc. Methods to control protein heterogeneity
SG11201507230PA (en) 2013-03-12 2015-10-29 Abbvie Inc Human antibodies that bind human tnf-alpha and methods of preparing the same
US9017687B1 (en) 2013-10-18 2015-04-28 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same using displacement chromatography
WO2014159579A1 (en) 2013-03-14 2014-10-02 Abbvie Inc. MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE
WO2014151878A2 (en) 2013-03-14 2014-09-25 Abbvie Inc. Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
WO2014209508A1 (en) * 2013-05-13 2014-12-31 Medimmune, Llc Separation of recombinant polyclonal antibody multimers with minimal separation of monomers
US9598667B2 (en) 2013-10-04 2017-03-21 Abbvie Inc. Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
US9085618B2 (en) 2013-10-18 2015-07-21 Abbvie, Inc. Low acidic species compositions and methods for producing and using the same
US9181337B2 (en) 2013-10-18 2015-11-10 Abbvie, Inc. Modulated lysine variant species compositions and methods for producing and using the same
US8946395B1 (en) 2013-10-18 2015-02-03 Abbvie Inc. Purification of proteins using hydrophobic interaction chromatography
US20150139988A1 (en) 2013-11-15 2015-05-21 Abbvie, Inc. Glycoengineered binding protein compositions
CA2942134C (en) * 2014-03-04 2023-08-15 Merck Patent Gmbh Robust antibody purification
AR102198A1 (es) 2014-10-09 2017-02-08 Regeneron Pharma Proceso para reducir partículas subvisibles en una formulación farmacéutica
JP6845139B2 (ja) * 2014-12-15 2021-03-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 粗製溶液からの標的分子捕捉
CN105134271B (zh) * 2015-08-04 2017-06-16 山西晋城无烟煤矿业集团有限责任公司 综采工作面两端头过超高段液压支护装置
AU2017312785B2 (en) 2016-08-16 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
KR102759512B1 (ko) 2016-10-25 2025-02-03 리제너론 파아마슈티컬스, 인크. 크로마토그래피 데이터 분석을 위한 방법 및 시스템
WO2019060062A1 (en) 2017-09-19 2019-03-28 Regeneron Pharmaceuticals Inc. METHODS OF REDUCING PARTICLE FORMATION AND COMPOSITIONS FORMED THEREFROM
PL3731873T3 (pl) * 2017-12-29 2022-04-25 F. Hoffmann-La Roche Ag Sposób dostarczania kompozycji pegylowanego białka
US12208142B2 (en) 2017-12-29 2025-01-28 Hoffmann-La Roche Inc. Process for providing PEGylated protein composition
CN111818980B (zh) 2018-03-08 2022-10-11 生物辐射实验室股份有限公司 阴离子交换-疏水混合模式色谱树脂
TWI919355B (zh) 2018-07-02 2026-03-21 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
HUE068630T2 (hu) * 2018-12-10 2025-01-28 Amgen Inc Mutáns PiggyBac transzpozáz
EA202192422A1 (ru) 2019-03-05 2021-12-09 Ридженерон Фармасьютикалз, Инк. Человеческий сывороточный альбумин в составах
GB201911686D0 (en) * 2019-08-15 2019-10-02 Fujifilm Diosynth Biotechnologies Uk Ltd Process for purifying target substances
CN114040815B (zh) * 2019-09-05 2024-06-28 生物辐射实验室股份有限公司 阴离子交换-疏水混合模式色谱树脂
KR20260058863A (ko) * 2019-09-24 2026-04-29 리제너론 파아마슈티컬스, 인크. 크로마토그래피의 사용 및 재생을 위한 시스템 및 방법
CN116375879A (zh) * 2021-12-16 2023-07-04 信达生物制药(苏州)有限公司 B7-h3免疫缀合物及其应用
US20230331773A1 (en) * 2022-04-15 2023-10-19 Pall Corporation Chromatography device and method of use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4118912C1 (es) * 1991-06-08 1992-07-02 Biotest Pharma Gmbh, 6072 Dreieich, De
EP1681299B1 (en) 2000-03-27 2009-11-11 Genetics Institute, LLC Methods for purifying highly anionic proteins
US20040002081A1 (en) * 2001-12-18 2004-01-01 Boehringer Ingelheim International Gmbh And Bia Separations D.O.O. Method and device for isolating and purifying a polynucleotide of interest on a manufacturing scale
US20060257972A1 (en) * 2003-03-31 2006-11-16 Takashi Ishihara Purification of human monoclonal antibody and human polyclonal antibody
WO2004087765A1 (ja) 2003-03-31 2004-10-14 Toto Ltd. 分子識別能を有する二酸化チタン複合体
US20060027454A1 (en) 2004-08-09 2006-02-09 Dinovo Augustine Procedure for the fractionation of proteins by using sequential ion exchange and hydrophobic interaction chromatography as prefractionation steps before analysis by two dimensional electrophoresis
EP1963367A4 (en) 2005-12-06 2009-05-13 Amgen Inc POLISHING STEPS IN MULTI-STAGE PROTEIN PURIFICATION TREATMENTS
PT2253644E (pt) * 2005-12-20 2014-01-23 Bristol Myers Squibb Co Composições e métodos para a produção de uma composição
CA2632328A1 (en) * 2005-12-22 2007-06-28 Ge Healthcare Bio-Sciences Ab Preparation of biomolecules
CN102391358B (zh) * 2006-04-05 2016-08-10 艾伯维生物技术有限公司 抗体纯化
KR20090058532A (ko) * 2006-08-28 2009-06-09 아레스 트레이딩 에스.에이. Ｆｃ­융합 단백질을 정제하는 방법
US20100056759A1 (en) * 2006-10-19 2010-03-04 Tolerx, Inc. Methods and Compositions for Efficient Removal of Protein A from Binding Molecule Preparations
WO2008085988A1 (en) * 2007-01-05 2008-07-17 Amgen Inc. Methods of purifying proteins
JP2010516651A (ja) * 2007-01-17 2010-05-20 メルク セローノ ソシエテ アノニム Ｆｃ含有タンパク質の精製のための方法
WO2009058769A1 (en) * 2007-10-30 2009-05-07 Schering Corporation Purification of antibodies containing hydrophobic variants
US9527010B2 (en) * 2009-09-25 2016-12-27 Ge Healthcare Bio-Sciences Corp. Separation system and method

Also Published As

Publication number Publication date
CN102762585B (zh) 2016-01-20
KR20120118065A (ko) 2012-10-25
AR080163A1 (es) 2012-03-21
CA2787897A1 (en) 2011-08-18
AU2011214361A1 (en) 2012-08-23
WO2011098526A1 (en) 2011-08-18
CN102762585A (zh) 2012-10-31
TW201144327A (en) 2011-12-16
JP2013519652A (ja) 2013-05-30
AU2011214361C1 (en) 2016-01-14
EP2534169A1 (en) 2012-12-19
AU2011214361B2 (en) 2014-12-04
US20130131318A1 (en) 2013-05-23
BR112012020254A2 (pt) 2016-05-03
EA201201132A1 (ru) 2013-03-29
MX2012009283A (es) 2012-09-07
IL221072A0 (en) 2012-09-24

Similar Documents

Publication Publication Date Title
EA201390929A1 (ru) Антитела к pcsk9 и способы их применения
CL2012002884A1 (es) Polipeptido que comprende un dominio decimo de fibronectina de tipo iii que se unen a la proteina covertasa subtilisina kexina tipo q ( pcsk9); composicion farmacéutica que comprende dicho polipeptido.
UY34343A (es) Proteinas de unión al antígeno cd27l
EA201490265A1 (ru) Ингибиторы тирозинкиназы брутона
UY34228A (es) Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9
UY34394A (es) Polipéptidos de anticuerpos que antagonizan cd40l
CO6531429A2 (es) Inhibidores de la tirosina quinasa de bruton
CR20110544A (es) Anticuerpo antagonista específico para el heterodímero de alfa-4-beta-7
EA201300239A1 (ru) Антитела к fap и способы их применения
DK2637690T3 (da) Flydende ANTI-TNF-alpha-antistofformuleringer med høj koncentration
UY33958A (es) Inhibidores de la glucosilceramida sintasa
CL2013000930A1 (es) Anticuerpo para interleuquina 17 (il-17); uso de dicho anticuerpo para tratar soriasis usando antagonistas de il-17.
MX2019002979A (es) Formulaciones de anticuerpos.
DK2419429T3 (da) Imidazopyraziner som inhibitorer af proteinkinaser
CL2016001166A1 (es) Silicato de zirconio microporoso para el tratamiento de la hipercalemia
CO7111273A2 (es) Anticuerpos cd47 y métodos de uso de los mismos
CL2011002943A1 (es) Anticuerpo triespecifico o tetraespecifico; metodo para la preparacion de dicho anticuerpo; celula huesped; composicion farmaceutica.
CY2017021I1 (el) Υψηλης συναφειας ανθρωπινα αντισωματα προς pcsk9
DK2643018T3 (da) Anti-il-6-antistoffer til behandling af oral mucositis
CR20140212A (es) Anticuerpos anti-htra1 y métodos de uso
AR088920A1 (es) Purificacion de anticuerpos anti-c-met
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
EP2367974A4 (en) MODIFICATION OF BIOMASS FOR EFFICIENT CONVERSION TO FUEL
UA109931C2 (xx) Піримідинциклогексильні модулятори глюкокортикоїдних рецепторів
EA201390669A1 (ru) Способы и композиции для иммунотерапии заболеваний нервной системы